Galecto, Inc. (GLTO) 10-Year Financial Performance & Capital Metrics

GLTO • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.Show more

Revenue $0
EBITDA -$22M +43.5%
Net Income -$21M +44.1%
EPS (Diluted) -18.53 +48.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -89.03% -9.2%
ROIC -259.97% -77.6%
Debt/Equity 0.00 -40.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM25.17%

EPS CAGR

10Y-

5Y-

3Y-

TTM34.42%

ROCE

10Y Avg-64.74%

5Y Avg-62.57%

3Y Avg-81.56%

Latest-92.11%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	111K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	-111K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	1%	-	-	-	-
Operating Expenses+	12.91M	38.97M	33.64M	52.23M	61.21M	39.91M	22.26M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	2.81M	2.44M	9.01M	13.74M	13M	12.69M	10.5M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	10.09M	36.53M	24.63M	38.49M	48.21M	23.77M	10.79M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	3.45M	968K
Operating Income+	-12.91M	-38.97M	-33.64M	-52.23M	-61.21M	-39.91M	-22.26M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.02%	0.14%	-0.55%	-0.17%	0.35%	0.44%
EBITDA+	-12.89M	-38.86M	-33.45M	-51.79M	-60.72M	-39.08M	-22.08M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-2.01%	0.14%	-0.55%	-0.17%	0.36%	0.43%
D&A (Non-Cash Add-back)	12.91K	111K	188K	441K	490K	830K	181K
EBIT	-12.9M	-36.51M	-34.84M	-52.23M	-61.21M	-36.46M	-21.29M
Net Interest Income+	0	0	0	156K	305K	1.69M	844K
Interest Income	0	0	0	156K	722K	1.69M	844K
Interest Expense	2.97M	0	0	0	417K	0	0
Other Income/Expense	-2.96M	2.46M	-1.2M	475K	-417K	1.56M	862K
Pretax Income+	-15.87M	-36.51M	-34.84M	-51.75M	-61.62M	-38.35M	-21.4M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	41K
Effective Tax Rate %	1%	1.05%	1%	1%	1%	1%	1%
Net Income+	-15.87M	-38.42M	-34.84M	-51.75M	-61.62M	-38.35M	-21.44M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-1.42%	0.09%	-0.49%	-0.19%	0.38%	0.44%
Net Income (Continuing)	-15.87M	-36.51M	-34.84M	-51.75M	-61.62M	-38.35M	-21.44M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-4.42	-37.76	-35.66	-50.75	-61.04	-36.08	-18.53
EPS Growth %	-	-7.54%	0.06%	-0.42%	-0.2%	0.41%	0.49%
EPS (Basic)	-4.42	-37.76	-35.66	-50.75	-61.04	-36.08	-18.53
Diluted Shares Outstanding	1.02M	1.02M	1.01M	1.01M	1.02M	1.06M	1.16M
Basic Shares Outstanding	1.02M	1.02M	1.01M	1.01M	1.02M	1.06M	1.16M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	34.96M	56.08M	169.29M	110.1M	63.91M	36.77M	16.84M
Cash & Short-Term Investments	30.99M	11.29M	163.58M	100.19M	60.22M	33.15M	14.18M
Cash Only	30.99M	11.29M	163.58M	62.56M	32.79M	21.46M	14.18M
Short-Term Investments	0	0	0	37.63M	27.44M	11.69M	0
Accounts Receivable	989K	41.13M	2.21M	2.28M	1.38M	1.72M	881K
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	2.97M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	2.98M	3.66M	1.86M	5.9M	1.5M	1.13M	1.19M
Total Non-Current Assets+	144K	529K	2.3M	12.11M	9.28M	1.45M	293K
Property, Plant & Equipment	0	298K	885K	1.04M	1.17M	325K	130K
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	144K	231K	0	9.05M	5.83M	0	0
Other Non-Current Assets	0	0	1.42M	2.03M	2.28M	1.13M	163K
Total Assets+	35.1M	56.61M	171.6M	122.22M	73.19M	38.23M	17.13M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	0.61%	2.03%	-0.29%	-0.4%	-0.48%	-0.55%
Total Current Liabilities+	4.44M	7.93M	5.57M	4.54M	11.11M	5.83M	1.2M
Accounts Payable	1.41M	3.33M	2.85M	1.53M	3.35M	1.7M	377K
Days Payables Outstanding	-	10.95K	-	-	-	-	-
Short-Term Debt	0	87K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	2.88M	4.4M	1.37M	1.04M	7.28M	2.96M	691K
Current Ratio	7.87x	7.07x	30.42x	24.23x	5.75x	6.31x	14.07x
Quick Ratio	7.20x	7.07x	30.42x	24.23x	5.75x	6.31x	14.07x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	211K	541K	448K	328K	66K	104K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	211K	541K	448K	328K	66K	61K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	43K
Total Liabilities	4.44M	8.14M	6.11M	4.99M	11.44M	5.9M	1.3M
Total Debt+	0	298K	915K	847K	804K	249K	73K
Net Debt	-30.99M	-11M	-162.67M	-61.72M	-31.98M	-21.22M	-14.1M
Debt / Equity	-	0.01x	0.01x	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-4.35x	-	-	-	-146.78x	-	-
Total Equity+	30.66M	48.47M	165.49M	117.22M	61.75M	32.33M	15.83M
Equity Growth %	-	0.58%	2.41%	-0.29%	-0.47%	-0.48%	-0.51%
Book Value per Share	30.14	47.64	163.77	116.01	60.76	30.42	13.68
Total Shareholders' Equity	30.66M	48.47M	165.49M	117.22M	61.75M	32.33M	15.83M
Common Stock	0	0	0	0	0	0	0
Retained Earnings	-33.02M	-69.52M	-104.36M	-156.11M	-217.74M	-256.08M	-277.52M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-1.64M	-2.45M	674K	-320K	-244K	380K	97K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.69M	-19.33M	-38.2M	-52.31M	-42.93M	-36.91M	-18.62M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.41%	-0.98%	-0.37%	0.18%	0.14%	0.5%
Net Income	-15.87M	-36.51M	-34.84M	-51.75M	-61.62M	-38.35M	-21.44M
Depreciation & Amortization	0	111K	188K	441K	490K	830K	181K
Stock-Based Compensation	81K	0	982K	4.48M	5.57M	5.43M	3.24M
Deferred Taxes	0	0	0	1.07M	0	0	0
Other Non-Cash Items	3.03M	14.88M	55K	75K	694K	-449K	2.06M
Working Capital Changes	-933K	2.19M	-4.59M	-6.62M	11.94M	-4.37M	-2.67M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	733K	1.94M	-477K	-1.32M	1.82M	-1.65M	-1.32M
Cash from Investing+	0	-326K	0	-48.05M	12.38M	22.33M	11.65M
Capital Expenditures	0	0	0	-223K	-196K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	-47.83K	-70K	83K	0
Cash from Financing+	42.87M	0	187.39M	0	507K	2.88M	0
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	34.36M	0	-4.95M	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-13.69M	-19.33M	-38.2M	-52.53M	-43.13M	-36.91M	-18.62M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.41%	-0.98%	-0.38%	0.18%	0.14%	0.5%
FCF per Share	-13.46	-19.00	-37.81	-51.99	-42.43	-34.73	-16.09
FCF Conversion (FCF/Net Income)	0.86x	0.50x	1.10x	1.01x	0.70x	0.96x	0.87x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-51.76%	-97.1%	-32.56%	-36.61%	-68.86%	-81.52%	-89.03%
Return on Invested Capital (ROIC)	-	-157.36%	-125.21%	-134.31%	-107.66%	-146.4%	-259.97%
Debt / Equity	-	0.01x	0.01x	0.01x	0.01x	0.01x	0.00x
Interest Coverage	-4.35x	-	-	-	-146.78x	-	-
FCF Conversion	0.86x	0.50x	1.10x	1.01x	0.70x	0.96x	0.87x

Frequently Asked Questions

Growth & Financials

Galecto, Inc. (GLTO) grew revenue by 0.0% over the past year. Growth has been modest.

Galecto, Inc. (GLTO) reported a net loss of $15.8M for fiscal year 2024.

Dividend & Returns

Galecto, Inc. (GLTO) has a return on equity (ROE) of -89.0%. Negative ROE indicates the company is unprofitable.

Galecto, Inc. (GLTO) had negative free cash flow of $12.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener